Research into hepatic and intestinal CYP3A4 activities by means of intravenous and oral midazolam and budesonide in patients with Crohn’s disease and celiac disease has detected a marked drop of CYP3A4 activity in vivo in patients with celiac disease [424]. Here, CYP3A4 is linked to Crohn disease.